The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 7, Pages e101889
Publisher
Public Library of Science (PLoS)
Online
2014-07-09
DOI
10.1371/journal.pone.0101889
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer
- (2013) Mhd Yaser Al-Marrawi et al. CANCER BIOLOGY & THERAPY
- Multi-kinase modulation for colon cancer therapy
- (2013) Paul Dent CANCER BIOLOGY & THERAPY
- Brucine suppresses colon cancer cells growthviamediating KDR signalling pathway
- (2013) Wenjuan Luo et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Design, synthesis and in vitro antitumor evaluation of novel diaryl urea derivatives bearing sulfonamide moiety
- (2013) Can Luo et al. Science China-Chemistry
- Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma
- (2012) Masatoshi Kudo WORLD JOURNAL OF GASTROENTEROLOGY
- Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer
- (2012) Ming Yu et al. Therapeutic Advances in Gastroenterology
- Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat
- (2011) Xue-qing Wang et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude mice
- (2010) Dongdong Wu et al. PEPTIDES
- Mitogen-activated protein kinases in hepatocellular carcinoma development
- (2010) Lihua Min et al. SEMINARS IN CANCER BIOLOGY
- Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
- (2009) Ymera Pignochino et al. Molecular Cancer
- Review: Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies
- (2009) Sonja K. Olsen et al. Therapeutic Advances in Gastroenterology
- Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents
- (2008) M. CHAPARRO et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
- (2008) W. L. Dahut et al. CLINICAL CANCER RESEARCH
- In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer–5-fluorouracil conjugates
- (2008) Fang Yuan et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Amentoflavone Inhibits Experimental Tumor Metastasis Through a Regulatory Mechanism Involving MMP-2, MMP-9, Prolyl Hydroxylase, Lysyl Oxidase, VEGF, ERK-1, ERK-2, STAT-1, nm23 and Cytokines in Lung Tissues of C57BL/6 Mice
- (2008) Chandrasekaran Guruvayoorappan et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now